Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.

Several small single-center studies have reported a prognostic role for Ki-67 labeling index in advanced urothelial carcinoma of the urinary bladder. To investigate whether Ki-67 was a useful biomarker of oncological outcome after radical cystectomy for urothelial carcinoma, we assessed its expression in tumor tissue from 713 patients treated with radical cystectomy and bilateral lymphadenectomy at six centers. A high Ki-67 labeling index was independently associated with established features of aggressive urothelial carcinoma, disease recurrence, and cancer-specific survival. Addition of Ki-67 labeling index improved the accuracy of standard multivariate outcome prediction models, as measured by Harrell concordance index, by 2.9% for disease recurrence and 2.4% for bladder cancer-specific survival (P < .001, two-sided Mantel-Haenszel) -- a statistically and potentially clinically significant margin. In conclusion, routine assessment of Ki-67 expression status along with assessment of other established predictors of urothelial carcinoma outcome has the potential to improve identification of patients who are at increased risk for disease progression after radical cystectomy and thus may benefit from perioperative systemic chemotherapy.

[1]  F. Montorsi,et al.  Predicting survival after radical cystectomy for bladder cancer , 2008, BJU international.

[2]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[3]  Yair Lotan,et al.  Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy , 2008, Cancer.

[4]  Wun-Jae Kim Multiple biomarkers improve prediction of bladder cancer progression and cancer specific survival , 2008 .

[5]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[6]  Y. Lotan,et al.  Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.

[7]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[8]  Y. Noguchi,et al.  Growth index, assessed with Ki‐67 and ssDNA labeling; a significant prognosticator for patients undergoing curative resection for hepatocellular carcinoma , 2005, Journal of surgical oncology.

[9]  E. Messing,et al.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. , 2005, Urology.

[10]  D. Elder,et al.  Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Grignon,et al.  Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy , 2004, Clinical Cancer Research.

[12]  C. Vale Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[13]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[14]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[15]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Hoznek,et al.  The prognostic value of p53 nuclear overexpression and MIB‐1 as a proliferative marker in transitional cell carcinoma of the bladder , 1997, Cancer.

[17]  Y. Takano,et al.  Prognostic significance of Ki-67 expression in transitional cell bladder carcinoma after radical cystectomy. , 1997, Pathology, research and practice.

[18]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[19]  F. Freiha,et al.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. , 1996, Journal of Urology.

[20]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[21]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[22]  M. Stöckle,et al.  Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. , 1992, The Journal of urology.

[23]  W. H. Kern,et al.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. , 1991, The Journal of urology.

[24]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.